middle.news
Immutep’s Efti Plus KEYTRUDA® Boosts Survival in Tough Head and Neck Cancer Cases
3:25am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Immutep’s Efti Plus KEYTRUDA® Boosts Survival in Tough Head and Neck Cancer Cases
3:25am on Monday 2nd of June, 2025 AEST
Key Points
17.6-month median overall survival in PD-L1 CPS <1 head and neck cancer patients
Combination therapy outperforms historical standard-of-care treatments
Well-tolerated with no new safety concerns reported
FDA meeting requested to discuss regulatory approval pathways
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
IMM
OPEN ARTICLE